drugset / Trial / NCT06335849
A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
Phase 1
Active not recruiting
48 enrolled
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.
Timeline
- Start
- 2024-03-27
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LYB004 | Vaccine | 25 ug | Intramuscular |
| Subject | LYB004 | Vaccine | 50 ug | Intramuscular |
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | Intramuscular |